Evidence map›Paper›PMID 35989319›Full record

ArticleGenome medicine2022

High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.

Viola Dreyer, Ayan Mandal, Prachi Dev, Matthias Merker, Ivan Barilar, Christian Utpatel, Kayzad Nilgiriwala, Camilla Rodrigues, Derrick W Crook, CRyPTIC Consortium and 4 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Extensive Endemic Transmission of Multidrug-ResistantOpen forum infectious diseases · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. OASIS: An interpretable, finite-sample valid alternative to Pearson'sProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 5 countries.

Viola Dreyer *Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Ayan Mandal *The Foundation for Medical Research, Mumbai, India.
Prachi Dev *The Foundation for Medical Research, Mumbai, India.
Matthias MerkerMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Ivan BarilarMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Christian UtpatelMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Kayzad NilgiriwalaThe Foundation for Medical Research, Mumbai, India.
Camilla RodriguesDepartment of Microbiology, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
Derrick W CrookCRyPTIC Consortium, Oxford, UK.
CRyPTIC Consortium
Jean-Philippe RasigadeCentre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, University of Lyon, Lyon, France.
Thierry WirthInstitut de Systématique, Evolution, Biodiversité, UMR-CNRS 7205, Muséum National d'Histoire Naturelle, Université Pierre Et Marie Curie, Université Des Antilles, Ecole Pratique Des Hautes Etudes, Sorbonne Universités, Paris, France.
Nerges Mistry *The Foundation for Medical Research, Mumbai, India.
Stefan Niemann *Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany. sniemann@fz-borstel.de.ORCID http://orcid.org/0000-0002-6604-0684
Foundation for Medical Research · INResearch Center Borstel - Leibniz Lung Center · DEGerman Center for Infection Research · DEUniversity of Oxford · GBP. D. Hinduja Hospital and Medical Research Centre · INCentre National de la Recherche Scientifique · FRLaboratoire de l'Intégration du Matériau au Système · FRStanford Medicine · USUniversité Claude Bernard Lyon 1 · FRUniversity of Surrey · GB

Funding

Wellcome TrustWellcome Trust 200205/Z/15/Z
6 · The paper itself

Abstract

backgroundMultidrug-resistant (MDR) Mycobacterium tuberculosis complex (MTBC) strains are a serious health problem in India, also contributing to one-fourth of the global MDR tuberculosis (TB) burden. About 36% of the MDR MTBC strains are reported fluoroquinolone (FQ) resistant leading to high pre-extensively drug-resistant (pre-XDR) and XDR-TB (further resistance against bedaquiline and/or linezolid) rates. Still, factors driving the MDR/pre-XDR epidemic in India are not well defined.

methodsIn a retrospective study, we analyzed 1852 consecutive MTBC strains obtained from patients from a tertiary care hospital laboratory in Mumbai by whole genome sequencing (WGS). Univariate and multivariate statistics was used to investigate factors associated with pre-XDR. Core genome multi locus sequence typing, time scaled haplotypic density (THD) method and homoplasy analysis were used to analyze epidemiological success, and positive selection in different strain groups, respectively.

resultsIn total, 1016 MTBC strains were MDR, out of which 703 (69.2%) were pre-XDR and 45 (4.4%) were XDR. Cluster rates were high among MDR (57.8%) and pre-XDR/XDR (79%) strains with three dominant L2 (Beijing) strain clusters (Cl 1-3) representing half of the pre-XDR and 40% of the XDR-TB cases. L2 strains were associated with pre-XDR/XDR-TB (P < 0.001) and, particularly Cl 1-3 strains, had high first-line and FQ resistance rates (81.6-90.6%). Epidemic success analysis using THD showed that L2 strains outperformed L1, L3, and L4 strains in short- and long-term time scales. More importantly, L2 MDR and MDR + strains had higher THD success indices than their not-MDR counterparts. Overall, compensatory mutation rates were highest in L2 strains and positive selection was detected in genes of L2 strains associated with drug tolerance (prpB and ppsA) and virulence (Rv2828c). Compensatory mutations in L2 strains were associated with a threefold increase of THD indices, suggesting improved transmissibility.

conclusionsOur data indicate a drastic increase of FQ resistance, as well as emerging bedaquiline resistance which endangers the success of newly endorsed MDR-TB treatment regimens. Rapid changes in treatment and control strategies are required to contain transmission of highly successful pre-XDR L2 strains in the Mumbai Metropolitan region but presumably also India-wide.

Indexed as

Extensively Drug-Resistant TuberculosisMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsClone CellsDrug Resistance, Multiple, BacterialFluoroquinolonesHumansMicrobial Sensitivity TestsMultilocus Sequence TypingRetrospective StudiesAntitubercular AgentsFluoroquinolonesFluoroquinolone resistanceIndia; Pre-XDR/XDR-TBMultidrug-resistant TBPre-XDR/XDR-TB transmissionResistant TBTransmission successTuberculosis

Identifiers

PMID35989319
PMCPMC9394022
OpenAlexW4294334402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.